Although higher pre-therapeutic PD-L1 levels in primary tumors are considered an indicator of increased sensitivity to anti-PD-1/PD-L1 therapy, the re-acquisition or uncontrollable PD-L1 expression on either tumor or immune cells is associated with therapeutic resistance to PD-1/PD-L1 blockades [27]. Here, CD274 is linked to neoplasm.